Baird Downgrades Biomarin Pharmaceutical to Neutral, Lowers Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has downgraded Biomarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Neutral and lowered the price target from $104 to $72.
May 17, 2024 | 9:20 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Baird analyst Joel Beatty downgraded Biomarin Pharmaceutical from Outperform to Neutral and reduced the price target from $104 to $72.
The downgrade from Outperform to Neutral and the significant reduction in the price target from $104 to $72 by a reputable analyst is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100